A cataract is a clouding of the lens in the eye that affects vision. Most cataracts are related to aging. Cataracts are very common in older people.
By age 80, more than half of all Americans either have a cataract or have had cataract surgery.
A cataract can occur in either or both eyes. It cannot spread from one eye to the other.
Cataract surgery is an operation to remove your eye’s lens when it is cloudy.
The purpose of your lens is to bend (refract) light rays that come into the eye to help you see. Your own lens should be clear, but with a cataract it is cloudy. Having a cataract can be like looking through a foggy or dusty car windshield. Things may look blurry, hazy or less colorful.
The only way to remove a cataract is with surgery. Your ophthalmologist will recommend removing a cataract when it keeps you from doing things you want or need to do.
During cataract surgery, your cloudy natural lens is removed and replaced with a clear artificial lens. That lens is called an intraocular lens (IOL). Your ophthalmologist will talk with you about IOLs and how they work.
Any type of surgery creates an incision, and this promotes release of inflammatory factors. Cataract surgery, while the incision is very small, creates inflammation in the cornea, anterior chamber, and iris. Also, microscopic remnants of the cataract are often left in the anterior chamber of the eye, which lead to continued release of inflammatory factors. Topical anti-inflammatory agents are beneficial at removing all the inflammatory factors and clearing the vision, thus they are very important to use after any intraocular surgery.
OCS-01 successfully completed a Phase 2 trial in Inflammation and Pain following cataract surgery (SKYGGN trial) with 153 patients providing the first proof-of-concept of a once daily topical steroid. A long-acting topical solution, such as OCS-01, has the potential of reducing the burden of administration given that patients undergoing cataract surgery are usually on several medications daily.
OCS-01 also successfully completed another Phase 2 trial in DME. Following the completion of both Phase 2 trials, an End of Phase 2 meeting was conducted with FDA and the product candidate is now moving into phase III in both indications.
OCS-01 has been developed using the OPTIREACH solubilizing nanoparticle technology, a proprietary platform that enables the formulation of drugs as non-invasive topical treatments, a longer residence time on the eye surface and enhances their bioavailability in the relevant eye tissues.
To learn more about the SKYGGN Phase 2 Study Results of OCS-01 for the treatment of Inflammation and Pain following cataract surgery, please click here